Epigenetic Tests Lack Transparency and Regulation

M

Matt Kaeberlein, The Optispan Podcast

Quotes From Source

“There's no transparency on quality control.”

Story of claim

Matt Kaeberlein criticizes companies selling epigenetic tests for their lack of transparency and regulation. He points out the absence of quality control measures and potential cost-cutting due to profit incentives.

  • Goal: Critique the transparency and regulation in the epigenetic testing market.
  • Proof: Companies are not Clea certified, leaving uncertainty about their operations and quality control.
  • Nuances:
    • Tests are sold outside of research settings without oversight.
    • Profit incentives may lead to cost-cutting and corner-cutting.
  • Impact on Life: Consumers may be misled about their biological age, affecting their perception of health.

Investments

  • Price: $100-200 per test
  • Time: 10 minutes to take a test, results in 2-4 weeks
  • Effort: Minimal effort, just collecting a sample and sending it for testing

Risks

Potential for inaccurate results due to lack of oversight.

Alternatives

  • Consult with healthcare professionals for validated health assessments.

Get Started 🚀

  • Research the company offering the test.
  • Check for any available certifications or quality assurance.
  • Consider alternative methods for health assessment.

Brogevity AI can make mistakes. Check important info.

Reference Video